Skip to content

Basket

You currently have no items in your basket.

Cape Biologix Technologies

Cape Biologix Technologies, a subsidiary of Cape Bio Pharms, utilizes plant-based expression platforms to improve the health and well-being of people and animals. Started in 2020 with the mission to contribute to global biosecurity through manufacturing high quality plant-based proteins that are accessible and economical. Their transient plant-based expression platform provides a compelling competitive alternative to traditional expression platforms through its superior speed, quality, flexibility, scalability, and sustainability.

View All Cape Biologix Technologies Products
Cape Biologix Technologies

What is transient plant-based expression?
 

Using their PtXPro™ technology, Cape Biologix Technologies converts thousands of Nicotiana Benthamiana plants into mini single-use, biodegradable bioreactors in their ISO 13458 certified facility. The plants, a distant cousin of tobacco, are infiltrated with Agrobacteria containing a gene of interest cloned into our plant expression vector that results in high yields of recombinant proteins within the leaves. These proteins can be used as research or diagnostic reagents and, under GMP compliance regulations, as therapeutic or vaccine candidates.

Their transient plant-based expression platform provides a compelling competitive alternative to traditional expression platforms through its superior speed, quality, flexibility, scalability, and sustainability.

 

What products do they make?

 

Cape Biologix Technologies product catalogue of PtX™ proteins currently includes monoclonal antibodies, proteins, and enzymes that are catered to research and development projects relating to various disease states including oncology, infectious diseases, neurodegenerative diseases, and general lab use. Their high-quality proteins can be used for a variety of applications, including Western Blot, ELISA, and Lateral Flow.